RCI Hospitality (RICK) Q2 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Greetings, and welcome to RCI Hospitality Holdings second quarter twenty twenty five earnings conference call. You can find the company's presentation on RCI's website. Go to the Investor Relations section, and all the links are at the top of the page. Please turn with me to Slide two of our presentation. I'm Mark Moran of Equity Animal, and I'll be hosting our call today. I'm coming to you from Washington, D. C. Eric Lange, Pres ...

Financial Data and Key Metrics Changes - Revenues for Q1 2025 were $130.4 million, with EBITDAR at $20.2 million, maintaining operating margins consistent with Q1 of the previous year despite challenges [4][5] - The impact of weather, leap year, and lower sports betting revenue in Colorado was estimated to reduce EBITDAR by approximately $2 million compared to Q1 of last year [5][25] - Carded gaming revenue increased by 1%, while uncarded gaming revenue decreased by 2.5% across all U.S. properties [5] Business Line Data and Key Metrics Changes - In Missouri, the new Caradasil property saw carded gaming revenue grow by 12% and uncarded revenue increase by 23%, leading to a total gaming revenue increase of 17% or $2.1 million compared to Q1 of last year [6][7] - The Century Casino and Hotel in Cape Girardeau experienced a 5% increase in patrons and a 2% increase in trips, although gaming win was flat due to lower hold [10][11] - In Colorado, carded revenue grew by 7% in Central City, while uncarded revenue decreased by 36% [12][13] Market Data and Key Metrics Changes - Total visitor volume decreased by 3%, with a notable reduction in visits from the 50 age group, partially offset by a 1% increase from younger guests [6] - The number of patrons living more than 75 miles from the new Caradasil property increased by 34%, contributing to a 23% increase in total visitors [8] - In the East segment, gaming revenue from upper-tier customers increased by 10%, while lower-tier customers saw a decline [15][16] Company Strategy and Development Direction - The company is focusing on expanding its market presence, particularly in Missouri, by targeting customers living 75 miles or more from its properties [12][54] - There is an emphasis on operational discipline and cost management to improve profitability, with plans to enhance marketing initiatives to attract higher net worth guests [11][54] - The company is also finalizing partnership agreements for sports betting in Missouri, expected to provide high-margin EBITDAR [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving consumer behavior and spending patterns since mid-March, with April showing an estimated 5% increase in EBITDA compared to last year [25][26] - Despite economic uncertainties, management is confident in the long-term prospects of the company, noting no significant competitive supply issues anticipated for this year or next [26][27] - The company plans to balance its capital expenditures with shareholder returns, indicating a cautious approach to stock buybacks in light of market conditions [27] Other Important Information - The company reported a cash position of approximately $85 million and no debt maturities until 2029, with expectations for net debt to EBITDA ratios to decrease significantly by year-end [23][24] - The company is committed to divesting its operations in Poland, with ongoing discussions with interested parties [22] Q&A Session Summary Question: Have you noticed any softening in consumer behavior for your Canadian assets? - Management indicated that lower revenue is not significant and attributed it to weather and one less gaming day, expressing no concerns [31][33] Question: Can you provide an update on initiatives at Rocky Gap? - Management confirmed completed renovations and marketing initiatives targeting Baltimore and Washington DC areas to attract higher net worth guests [35] Question: What has changed regarding year-end leverage targets? - Management acknowledged a positive trend since mid-March but remained cautious about projecting this trend for the full year [41][43] Question: Are you looking to monetize your casino database in Alberta? - Management mentioned potential partnerships with the Alberta Gaming Commission for database sharing but did not foresee other opportunities [44][47] Question: Are you focusing on revenue growth or maintaining EBITDA levels in Missouri? - Management aims for both revenue growth and cost discipline, particularly targeting the 75-mile customer base [52][54] Question: What is the timeline for divesting Polish assets? - Management believes divestment could occur in 2025 but acknowledged previous misestimations [55][56] Question: What is the capacity for stock buybacks? - Management plans to initiate stock buybacks with a single-digit million dollar volume between now and the next earnings release [57][58]

Core Insights - Planet Fitness, Inc. (PLNT) reported lower-than-expected first-quarter 2025 results, with adjusted earnings and revenues missing the Zacks Consensus Estimate, although both metrics increased year-over-year [1][4] - The company is facing macroeconomic volatility, increased costs, and expenses, particularly in SG&A and club operations [1][2] Financial Performance - Adjusted earnings per share (EPS) for Q1 2025 were 59 cents, missing the consensus estimate of 62 cents by 4.8%, while the prior-year quarter reported adjusted EPS of 53 cents [4] - Quarterly revenues were $276.7 million, lagging the consensus mark of $282 million by 1.7%, but rose 11.5% year-over-year due to new club openings and membership growth [4] - Adjusted EBITDA was $117 million, up 10% from $106.3 million reported in the year-ago quarter [5] Segment Performance - Franchise segment revenues rose 10.7% year-over-year to $115.2 million, with adjusted EBITDA of $84.9 million, up from $76.1 million [6] - Corporate-owned clubs generated revenues of $133.7 million, up 9.2% year-over-year, with adjusted EBITDA totaling $45.8 million, an increase from $42.4 million [7] - Equipment segment revenues totaled $27.8 million, up 28.7% year-over-year, with adjusted EBITDA rising to $7.4 million from $4.8 million [8] Cash and Debt Position - As of March 31, 2025, Planet Fitness had cash and cash equivalents of $343.9 million, up from $293.2 million at the end of 2024, while long-term debt decreased slightly to $2.14 billion [9] 2025 Outlook - For 2025, the company expects approximately 130-140 new equipment placements and 160-170 new club openings, with same-club sales growth projected in the 5-6% range [10] - Revenues are anticipated to increase approximately 10% from 2024 levels, with adjusted EBITDA and net income expected to grow around 10% and 8-9%, respectively [11] - Capital expenditures are now projected to increase approximately 20%, a revision from the previously expected 25% increase [12]

Protalix BioTherapeutics (PLX) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Company Participants Mike Moyer - Managing DirectorDror Bashan - President, CEO & DirectorEyal Rubin - SVP and CFODaniel Smith - Equity Research Associate Conference Call Participants John Vandermosten - Senior AnalystDan Akschuti - Equity Partner - Biotech AnalystNone - Analyst Operator Good morning, ladies and gentlemen, and welcome to the Protalix Biotherapeutics First Quarter twenty twenty five Financial and Business Results C ...

Sanuwave Health (SNWV) Q1 2025 Earnings Call May 09, 2025 08:30 AM ET Speaker0 Good day, everyone, and welcome to today's SANUWAVE Earnings Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note today's call will be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Chairman and CEO of SANUWAVE, Morgan Frank. Please go ahead. ...

Financial Data and Key Metrics Changes - The company reported total revenues of $197.1 million for Q1 2025, representing a year-over-year increase of 43% on an as-reported basis and 32% on an organic basis [8][28] - Adjusted non-GAAP EBITDA was $50.7 million, compared to $37.6 million in the prior year period, reflecting strong operational performance [32] - Adjusted non-GAAP EPS for the quarter was $1.7, up from $1.21 in the prior year period [32] Business Line Data and Key Metrics Changes - Revenues from the rare disease segment were $69 million, up 87% from the prior year, driven by strong performance of Cortrophin Gel, which generated $52.9 million in revenues, a 43% increase [29][30] - The generics segment reported revenues of $98.7 million, an increase of 41% year-over-year, attributed to new product launches and strong execution in the base business [14][30] - Revenues from the brands portfolio were $25.1 million, a slight decrease of 2% from the prior year [29] Market Data and Key Metrics Changes - The overall ACTH category grew 27% to approximately $684 million in 2024, indicating a favorable market environment for Cortrophin Gel [9] - The company expects Cortrophin Gel revenues to increase by 34% to 38% in 2025, projecting revenues of $265 million to $274 million [10][33] - The retina products, ILUVIEN and YUTIQ, generated revenues of $16.1 million in Q1, with performance impacted by market access challenges for Medicare patients [11][29] Company Strategy and Development Direction - The company is focused on expanding its rare disease business, particularly through Cortrophin Gel, and is investing in evidence generation and new product presentations to enhance market penetration [19][20] - A bespoke commercial approach is being implemented to address market access challenges, particularly for ILUVIEN and YUTIQ, with plans to enhance sales force capabilities [24][25] - The company is committed to maintaining a strong U.S. manufacturing footprint, with over 90% of revenues coming from domestically produced goods, positioning itself favorably in light of potential pharmaceutical tariffs [16][94] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Cortrophin Gel, citing a significant unmet medical need and a large addressable patient population [19][64] - The company anticipates a return to sequential revenue growth in the latter half of 2025, following a strong first quarter performance [34] - Management acknowledged challenges in the retina segment but highlighted positive trends in demand and a strengthened sales team as factors that will support future growth [13][53] Other Important Information - The company is preparing for an upcoming trial with CG Oncology regarding a royalty obligation dispute, with the jury trial set to commence on July 21, 2025 [36][38] - The company has a strong balance sheet with $149.8 million in unrestricted cash and a gross leverage ratio of 3.5 times [32] Q&A Session Summary Question: How much should the prefilled syringe help Cortrophin? - Management noted that early responses to the prefilled syringe have been positive, as it reduces one step in the administration process, and they expect to see traction as the year progresses [42][43] Question: What gives confidence in accelerating ILUVIEN and YUTIQ sales? - Confidence is based on several factors, including performance outside the U.S., improvements in sales force strength, and positive impacts from a bespoke commercial approach [51][52] Question: What are the payer dynamics for Cortrophin as the category returns to growth? - Management indicated that payers appreciate the competition brought to the category and that collaboration will continue to ensure patient access [82] Question: How is the acquisition of Alimera performing? - Management expressed confidence in the long-term opportunity for ILUVIEN and YUTIQ, highlighted by the recent buyout of a royalty obligation [84]

Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Devdatt Kurdikar - President & CEOJake Elguicze - Senior VP & CFOMarie Thibault - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Kallum Titchmarsh - AnalystMichael Polark - Senior Equity Research Analyst Devdatt Kurdikar And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of betwe ...

Financial Data and Key Metrics Changes - The company reported total revenues of $197.1 million for Q1 2025, representing a year-over-year increase of 43% on an as-reported basis and 32% on an organic basis [7][29] - Adjusted non-GAAP EBITDA was $50.7 million, compared to $37.6 million in the prior year period, reflecting strong operational performance [33] - Adjusted non-GAAP EPS for the quarter was $1.70, up from $1.21 in the prior year [33] Business Line Data and Key Metrics Changes - Revenues from the rare disease segment were $69 million, up 87% from the prior year, driven by strong performance of Cortrophin Gel, which generated $52.9 million in revenues, a 43% increase [30][33] - The generics segment reported revenues of $98.7 million, an increase of 41% year-over-year, attributed to new product launches and strong execution in the base business [14][31] - Revenues from the brands portfolio were $25.1 million, a decrease of 2% from the prior year, indicating a return to more normalized demand levels [30] Market Data and Key Metrics Changes - The overall ACTH category grew 27% to approximately $684 million in 2024, with Cortrophin Gel capturing a significant share of new prescribers [9][10] - The company expects Cortrophin Gel revenues to increase by 34% to 38% in 2025, reaching $265 million to $274 million [10][36] - The retina products, ILUVIEN and YUTIQ, generated revenues of $16.1 million in Q1, with expectations of $97 million to $103 million for the full year [10][36] Company Strategy and Development Direction - The company is focused on expanding its rare disease business, particularly through Cortrophin Gel, and is investing in new clinical trials to support its growth trajectory [20][28] - A strategic emphasis is placed on enhancing market access for ILUVIEN and YUTIQ through specialty pharmacies and Medicare Part D options [23][24] - The company is committed to maintaining a strong U.S. manufacturing footprint, with over 90% of revenues coming from domestically produced goods [16][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Cortrophin Gel, citing a significant unmet medical need and a large addressable market [19][20] - The company anticipates a return to sequential revenue growth in the latter half of 2025, following a modest decline in Q2 [36] - Management acknowledged challenges in the retina segment due to market access issues but remains optimistic about recovery and growth in the second half of the year [11][56] Other Important Information - The company raised its 2025 guidance for total revenues and adjusted non-GAAP EBITDA based on strong Q1 performance and favorable demand trends [7][36] - The company has a strong balance sheet with $149.8 million in unrestricted cash and a gross leverage ratio of 3.5 times [33][34] - The company is preparing for an upcoming trial against CG Oncology regarding a royalty obligation dispute [38][39] Q&A Session Summary Question: How much should the prefilled syringe help Cortrophin? - Management noted that early responses to the prefilled syringe have been positive, as it reduces administration steps, and they expect to update on its progress soon [44] Question: What gives confidence in accelerating ILUVIEN and YUTIQ sales? - Confidence is based on performance outside the U.S., improvements in the sales force, and positive April results from a bespoke commercial approach [54][56] Question: Can you elaborate on the commercial challenges impacting ILUVIEN? - Challenges stemmed from a lack of funding for co-pay support for Medicare patients, affecting access to therapy [62] Question: What indications are driving growth for Cortrophin? - Growth is seen across all specialties, with significant contributions from nephrology, rheumatology, and ophthalmology [88] Question: How does the company view the acquisition of Alimera? - Management remains confident in the long-term opportunity for ILUVIEN and YUTIQ, as evidenced by the recent buyout of a royalty obligation [82]

Castellum, Inc. Reports First Year-Over-Year Organic Revenue Growth with Q1 2025 Results Castellum, Inc. ("Castellum" or the "Company") (NYSE-American: CTM) announces revenue for the first quarter of 2025 was $11.7 million, an increase from $10.3 million in the fourth quarter of 2024 and up from $11.3 million in the first quarter of 2024 - www.castellumus.com VIENNA, Va., May 09, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. ("Castellum" or the "Company") (NYSE-American: CTM), a cybersecurity, electronic war ...

金十数据5月9日讯，晶圆代工龙头台积电公布2025年4月自结合并营收3495.67亿台币，较3月2859.56亿 台币增长22.24%、较去年同期2360.21亿元增长达48.11%，刷新历史新高。累计前4月合并营收1.18兆台 币，较去年同期8286.65亿台币增长达43.46%，续创同期新高。展望第二季，台积电预期合并营收将升 至284~292亿美元，在新台币平均汇率32.5元假设下，毛利率估57~59%、营益率估47~49%。以此推 算，台积电第二季营收中位数创9360亿台币新高，季增11.53%、年增35.97%，毛利率、营益率中位数 略降至58%、48%。 台积电4月营收年增逾48%，创历史新高 ...